Myrtelle Email Format
Biotechnology ResearchMassachusetts, United States2-10 Employees
Myrtelle Inc. is a clinical-stage biotechnology company developing gene therapies for neurological diseases, with a focus on rare central nervous system disorders. Its lead program targets Canavan disease, pursuing a treatment option for this severe condition. The company emphasizes patient-centered, innovation-driven research as it advances therapies for CNS disorders. It is based in Wakefield, Massachusetts. The company serves patients and the broader medical and research community seeking new therapies for CNS diseases. A May 2026 development has the company participating in the ASGCT Annual Meeting to present data on its lead Canavan disease program.